Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Launch date
Employees
Market cap
€4.8b
Enterprise valuation
€4.6b (Public information from Sep 2024)
Share price
$89.33 BPMC
Cambridge Massachusetts (HQ)
Authorizing premium user...